Investor-Focused Strategic Expansion: Richard Boyd Joins Hado Therapeutics as Business Mentor

Date: 30 June 2025

Hado Therapeutics Ltd, a translational biotech company targeting aggressive brain cancers, is pleased to announce the appointment of Richard Boyd as Business Mentor and Strategic Advisor to support the company’s commercial growth and investor readiness.

Richard Boyd is a recognised leader in the biotech and medtech sectors, having raised over £14 million in equity and grants across multiple university spinouts, including Invizius and VueKlar Cardiovascular. His experience spans IP development, regulatory strategy, and human clinical trials, with deep expertise in securing investment and scaling life science ventures.

Richard’s involvement comes at a critical inflexion point for Hado Therapeutics, as it progresses its lead candidate targeting glioblastoma. His role will focus on shaping a robust investment narrative, identifying funding pathways, and aligning commercial strategy with development milestones.

“Richard’s insight and credibility within the investor community provides a significant advantage as we advance toward Series A funding,” said Dr Sriharsha Kantamneni, CEO of Hado Therapeutics.

Richard Boyd commented, “Hado has a highly compelling proposition, addressing unmet needs in oncology with real translational potential. I look forward to supporting the team in building a scalable, investable company with strong clinical and commercial foundations.”